Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Accumulated Expenses (2016 - 2025)

IGC Pharma (IGC) has disclosed Other Accumulated Expenses for 12 consecutive years, with $146000.0 as the latest value for Q3 2025.

  • Quarterly Other Accumulated Expenses rose 102.78% to $146000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $146000.0 through Sep 2025, up 102.78% year-over-year, with the annual reading at $1.0 million for FY2025, 382.21% up from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $146000.0 at IGC Pharma, down from $401000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.0 million in Q1 2025, with the low at $72000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 3 years is $363333.3, with a median of $209000.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses crashed 41.9% in 2024, then soared 382.21% in 2025.
  • Over 3 years, Other Accumulated Expenses stood at $209000.0 in 2023, then soared by 243.06% to $717000.0 in 2024, then plummeted by 79.64% to $146000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $146000.0, $401000.0, and $1.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.